Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Dana-Farber in Royalty Monetization

August 5, 2016

NEW YORKCovington advised Dana-Farber Cancer Institute in its monetization of a portion of its interest in royalties related to its Programmed Death Ligand-1 (PD-L1) intellectual property. PD-L1 inhibitors are immuno-oncology drugs used for the treatment of various types of metastatic cancer.

CPPIB Credit Europe S.à r.l., a wholly owned subsidiary of Canada Pension Plan Investment Board, has paid $100 million upfront to acquire a portion of Dana-Farber’s royalty interests and has committed to pay up to $68 million in additional payments, subject to certain conditions.

The Covington corporate team included partner John Gourary and associate Rachel Beller. Advice was also provided by of counsel Martin Beeler (bankruptcy) and partner Robert Heller (tax). 


Share this article: